Author:
Wang Na,Yang Jin,Lyu Jun,Liu Qingqing,He Hairong,Liu Jie,Li Li,Ren Xuequn,Li Zhendong
Abstract
Abstract
Background
The objective of this study was to develop a practical nomogram for predicting the cancer-specific survival (CSS) of patients with small-intestine adenocarcinoma.
Methods
Patients diagnosed with small-intestine adenocarcinoma between 2010 and 2015 were selected for inclusion in this study from the Surveillance, Epidemiology, and End Results (SEER) database. The selected patients were randomly divided into the training and validation cohorts at a ratio of 7:3. The predictors of CSS were identified by applying both forward and backward stepwise selection methods in a Cox regression model. The performance of the nomogram was measured by the concordance index (C-index), the area under receiver operating characteristic curve (AUC), calibration plots, the net reclassification improvement (NRI), the integrated discrimination improvement (IDI), and decision-curve analysis (DCA).
Results
Multivariate Cox regression indicated that factors including age at diagnosis, sex, marital status, insurance status, histology grade, SEER stage, surgery status, T stage, and N stage were independent covariates associated with CSS. These factors were used to construct a predictive model, which was built and virtualized by a nomogram. The C-index of the constructed nomogram was 0.850. The AUC values indicated that the established nomogram displayed better discrimination performance than did the seventh edition of the American Joint Committee on Cancer TNM staging system in predicting CSS. The IDI and NRI also showed that the nomogram exhibited superior performance in both the training and validation cohorts. Furthermore, the calibrated nomogram predicted survival rates that closely corresponded to actual survival rates, while the DCA demonstrated the considerable clinical usefulness of the nomogram.
Conclusion
We have constructed a nomogram for predicting the CSS of small-intestine adenocarcinoma patients. This prognostic model may improve the ability of clinicians to predict survival in individual patients and provide them with treatment recommendations.
Funder
National Social Science Foundation of China
Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference34 articles.
1. Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR. Small bowel adenocarcinoma. Gastroenterol Clin N Am. 2016;45(3):447–57.
2. Williamson JM, Williamson RC. Small bowel tumors: pathology and management. J Med Assoc Thail. 2014;97(1):126–37.
3. Young JI, Mongoue-Tchokote S, Wieghard N, Mori M, Vaccaro GM, Sheppard BC, Tsikitis VL. Treatment and survival of small-bowel adenocarcinoma in the United States: a comparison with Colon Cancer. Dis Colon Rectum. 2016;59(4):306–15.
4. Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G. Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol. 2010;17(10):2728–32.
5. Zhang S, Yuan W, Zhang J, Chen Y, Zheng C, Ma J, Jiang Q, Zhao Y, Xu Q, Wang C. Clinicopathological features, surgical treatments, and survival outcomes of patients with small bowel adenocarcinoma. Medicine (Baltimore). 2017;96(31):e7713.